Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.
|ClinicalTrials.gov Identifier: NCT01707745|
Recruitment Status : Unknown
Verified October 2012 by Sivakami A Pai, Dubai Health Authority.
Recruitment status was: Recruiting
First Posted : October 16, 2012
Last Update Posted : October 16, 2012
Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).
Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.
|Condition or disease||Intervention/treatment||Phase|
|Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.||Procedure: Intravitreal Bevacizumab||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
Bevacizumab(Avastin) 0.75mg in 0.03 ml
Procedure: Intravitreal Bevacizumab
Other Name: Intravitreal Avastin
- Regression Of ROP [ Time Frame: Minimum 6 months follow up after intravitreal Avastin ]
- Recurrence of ROP [ Time Frame: minimum 6 months of follow up. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01707745
|Contact: Sivakami A Pai, MS, DNB, Phd||00971504148256|
|Contact: M A Dekhain, FRCS, MRCOpth||0097142195000 ext 6272||maDekhain@dha.gov.ae|
|United Arab Emirates|
|Dubai, UAE, United Arab Emirates|
|Contact: Sivakami A Pai, MS, DNB, Phd 00971504148256|
|Contact: Moza A Dekhain, MRCOpthal, FRCS 009712195000 ext 6272 maDekhain@dha.gov.ae|
|Principal Investigator: Sivakami A Pai, MS, DNB, Phd|
|Sub-Investigator: Afra M Lootah, MSc, FRCS|